Life Sciences · Pharmaceutical
Pharmaceutical Contingent Workforce Solutions
Resource GMP operations, submission cycles, inspection responses, and CMO oversight without committing permanent headcount to temporary peaks.
Pharmaceutical contingent workforce solutions from Viltis are built around the two forces that drive contract labor demand in pharma: the GMP manufacturing calendar and the submission calendar. Neither follows a headcount plan. A pre-approval inspection date, a Form 483 response deadline, a technical transfer to a new site, or a stability failure that triggers an investigation all create immediate demand for people who can work inside your quality system on day one. We manage that demand as a program instead of as a run of urgent exceptions.
Overview
Where pharmaceutical demand actually spikes
The triggers are recognizable across companies, and most are visible months before the requisition appears. That is the argument for planning them instead of reacting to them.
Pre-approval inspection preparation and post-inspection commitment remediation
Form 483 responses and consent decree obligations requiring sustained remediation capacity
Technical transfer between sites or to a contract manufacturer, including comparability work
NDA, ANDA, and BLA submission pushes requiring publishing, authoring, and review capacity
Deviation and CAPA backlogs after a quality event or a system implementation
Commercial launch scale-up, including serialization and supply chain readiness
Facility expansion or new line qualification requiring CQV capacity for a defined window
Overview
Roles pharmaceutical programs fill most often
Pharma contract demand skews toward roles that require documented GMP experience and cannot be filled from a general staffing pool. Quality assurance specialists reviewing batch records, deviation and CAPA investigators, aseptic processing and sterility assurance support, CQV and computer system validation engineers, regulatory operations and publishing staff, CMC and technical writers, and pharmacovigilance case processors are the consistent categories.
Because these people work inside your quality system, supplier qualification carries different weight than in general staffing. A supplier who understands the difference between a validation engineer and a qualification technician saves you a screening cycle on every requisition.
Overview
Managing contract labor across a CMO network
Pharmaceutical manufacturing is increasingly distributed across contract manufacturing organizations, and person-in-plant oversight is one of the fastest-growing contract labor categories we see. Those roles sit awkwardly in most programs. The worker is engaged by you, based at a third-party site, and performing quality oversight on your behalf.
The program handles the practicalities: site-specific access and safety requirements, training against both your quality system and the CMO's, travel and expense treatment, and reporting lines that keep the oversight independent of the site being overseen.
Overview
Inspection readiness and evidence
When an inspector asks how a non-employee performing batch record review was qualified, the answer needs to be a record rather than a recollection. Pharmaceutical programs therefore weight the qualification and retention controls heavily: role-based GMP training assigned at onboarding, completion verified before quality system access, and records retained well beyond assignment close.
The same discipline applies to the people who arrive to help with the inspection itself. Surge resources brought in for a PAI still need to be qualified for what they are being asked to do.
Overview
Cost control without losing the people who matter
Pharma contract labor is expensive because the expertise is scarce, and blunt rate reduction usually costs more than it saves when a remediation commitment slips. Our approach is to separate the categories: standardize and compete the repeatable roles hard, and protect access to the scarce capability through supplier relationships and, where it fits, a direct-sourced pool of contractors who have worked in your plants before.
Benefits
What pharmaceutical organizations get
Capacity aligned to the GMP calendar
Inspection dates, transfer schedules, and submission targets become planned demand rather than emergency requisitions raised three weeks out.
Suppliers who know GMP roles
Qualification weights documented pharmaceutical delivery, so submittals reflect people who have worked under a quality system rather than adjacent industries.
CMO oversight handled properly
Person-in-plant assignments get site-specific access, dual training, and reporting arrangements that keep oversight independent.
Inspection evidence on file
Training, qualification, and access records for contract personnel are retained against each assignment and available years later.
Remediation capacity that sustains
Consent decree and 483 commitments require capacity for quarters rather than weeks, which the program plans and staffs deliberately.
Rate strategy by category
Repeatable roles are competed aggressively while scarce GMP expertise is protected, instead of applying one blunt rate policy to both.
FAQ
Pharmaceutical contingent workforce FAQs
Can contract personnel perform batch record review and release activities?
Review activities are commonly performed by qualified contract personnel. Release decisions and other authority-bearing roles are governed by your quality system and, in some jurisdictions, by named-person requirements. The program applies your quality system's rules; it does not assume a general position.
How quickly can you resource a 483 response?
Faster where the program already exists, because supplier terms, rate cards, and the onboarding path are agreed and only the candidate decision remains. From a cold start, contracting and onboarding usually take longer than sourcing does. That is the main argument for building the program before you need it.
Do you support person-in-plant roles at contract manufacturers?
Yes. These assignments need explicit handling of CMO site access, dual training obligations, expense treatment, and independent reporting lines, all of which get designed into the program instead of negotiated per assignment.
How do you handle contractors across multiple manufacturing sites?
Each site typically carries its own access, safety, and training requirements. The program maintains site-specific onboarding paths while keeping a single intake, approval, and reporting structure, so multi-site workers are not onboarded from scratch at each location.
Is the program suitable for a company with a single commercial product?
Often yes, particularly where a CMO network and a small internal quality team mean contract labor is a large share of total effort. Scope is sized to that reality, not to a large-manufacturer template.
Continue
Related industry programs
Ready to talk through your program?
Bring us your current spend, supplier list, and compliance obligations. We will show you what a technology-enabled contingent workforce program would look like for your organization.